Roche: breakthrough designation for mosunetuzumab
(CercleFinance.com) - Roche announces that mosunetuzumab, its investigational immunotherapy for CD20xCD3 bispecific cancer, has received a breakthrough designation from the US FDA, based on favourable data from a Phase I/Ib study.
This designation, which is intended to accelerate drug development and review, is for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
Copyright (c) 2020 CercleFinance.com. All rights reserved.